...Awesome. Thank you, everybody, who has been joining all morning and pinging me with questions and making this a fun event again this year. Really happy to have Al Sandrock on, the head of R&D from Biogen here for this panel, where we're going to talk about a lot of stuff across Biogen's late-stage pipeline and just kind of thematically across neuroscience. I'm going to kick it off for a quick second by disappointing people, and hopefully, this will save my inbox from random aducanumab regulatory questions. And unfortunately, that just can't be the parameter of this discussion and Biogen can't really comment at this point in depth. So. But I do think we're still going to have a great chat because there's a lot of late-stage readouts this year. There's a lot of different things we can talk about in neuron. So with that, Al, thank you again for doing this panel....
